ETOPOPHOS® Injection Launch
H2-Pharma, LLC has entered into an agreement with CHEPLAPHARM Arzneimittel GmbH to be the exclusive U.S. distributor of ETOPOPHOS® (etoposide phosphate) for injection...
End-to-End Order Processing
H2-Pharma Automates Order Processing End-to-End—Including Chargeback Processing and Warehouse Order Fulfillment—with TrueCommerce EDI for QuickBooks Premier..
H2-Pharma, LLC has re-launched XENICAL® (orlistat) 120 mg Capsules via its newly formed Branded division. This opportunity arose due to the partnership with CHEPLAPHARM Arzneimittel GmbH...
Mayne Pharma, Inc.
H2-Pharma, LLC has acquired the exclusive rights to distribute fifteen (15) products from Mayne Pharma, Inc. In 2015 the combined market for these products was approximately $8.3 million according to IMS Health.